Faron Pharmaceuticals Ltd

Faron Pharma updates on Clevegen development as partner discussions advance

Markku Jalkanen, chief executive of Faron Pharmaceuticals Ltd (LON:FARN), updates Proactive London's Andrew Scott following the release of their 2018 results.

The company's main focus recently has been on Clevegen, its cancer immunotherapy which is currently undergoing a phase I/II study.

Meanwhile a second phase III study is now planned for its Traumakine treatment, subject to approval from regulators and external funding.

Quick facts: Faron Pharmaceuticals Ltd

Price: 185 GBX

Market: AIM
Market Cap: £80.09 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...



Investor Update: Faron Pharma applies to list on Nasdaq First North

Headlines from the Proactive UK newsroom. Finland-based Faron Pharmaceuticals (LON:FARN) is going home and has applied to list on Nasdaq First North Growth Market, a multilateral trading facility in Helsinki. Trading is set to start on 3 December. Oriole Resources (LON:ORR) has converted...

21 hours, 5 minutes ago


Holdings in Company

16 hours, 15 minutes ago

Price Monitoring Extension

21 hours, 14 minutes ago

Second Price Monitoring Extn

2 days, 19 hours ago

Price Monitoring Extension

2 days, 19 hours ago

Second Price Monitoring Extn

6 days, 19 hours ago

Price Monitoring Extension

6 days, 19 hours ago

Registration of Shares

1 week, 3 days ago

2 min read